LaNova Medicines
LaNova Medicines is a Chinese biopharmaceutical company focused on developing innovative cancer therapies. The company is advancing its pipeline with lead candidates such as LM-299, an anti-PD-1/VEGF bispecific antibody for advanced solid tumors, and other promising treatments targeting specific cancer pathways.
Leadership & Board
- Current Number of Employees
- 15
- Current LinkedIn Followers
- 632
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $42M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $42M
- Latest Funding Round
- Series C
- Post-Money Valuation
- ―
Employee Trend
LaNova Medicines had 15 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
15Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
LaNova Medicines had 632 followers as of October 12, 2026. The number of followers increased by 1 (0.16%) week-over-week.
632Latest Followers Count
1(0.16%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series C | $42.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Sino Biopharmaceuticals | Series C |
Similar Companies
A snapshot of private companies similar to LaNova Medicines, helping you discover and navigate related company profiles.
Related News and Analysis
